MI QUANTUMAI Trademark
MI QUANTUMAI is a USPTO trademark filed by Caris MPI, Inc.. Status: Pending.
Prosecution Summary
Trademark Summary
MI QUANTUMAI is a standard character service mark covering research information services in Class 42, including medical and scientific reports on cancer molecular profiling, genomic characteristics, and biosignatures via bioinformatics and AI, plus next-generation sequencing data; and medical information services in Class 44 for cancer diagnosis, treatment, and monitoring using similar sequencing technologies. The application is owned by Caris MPI, Inc., a Texas corporation based in Irving. Notice of Allowance issued October 21, 2025; applicant must file a Statement of Use or extension request within six months.
Recent Activity
Filed April 7, 2025, under intent-to-use basis and advanced through examination with an examiner's amendment entered July
Trademark Facts
| Mark | MI QUANTUMAI |
|---|---|
| Serial Number | 99124433 |
| Status | Pending |
| Filing Date | 2025-04-07 |
| Mark Type | Word |
| Nice Classes | 042 (Software & IT), 044 (Medical Services) |
| Owner | Caris MPI, Inc. |
| Attorney of Record | Anne Fleeson |
| Prosecution Events | 13 |
| Latest Event | NOAM on 2025-10-21 |
Goods & Services
Providing medical information to patients and medical professionals in the form of reports in the field of molecular profiling for the diagnosis, treatment and monitoring of cancer; providing medical information in the field of cancer based on next-generation sequencing (NGS), including whole exome sequencing (WES), whole transcriptome sequencing (WTS), and whole genome sequencing (WGS); Providing medical and scientific research information to researchers, patients and medical professionals in the form of reports in the field of molecular profiling for the characterization of cancer, genomic and transcriptomic characteristics, tumor microenvironment, and determination of biosignatures using bioinformatics and artificial intelligence; providing medical research information in the field of cancer based on next-generation sequencing (NGS), including whole exome sequencing (WES), whole transcriptome sequencing (WTS), and whole genome sequencing (WGS)